Silvia Lluesma-Martin
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Why advanced therapy medicinal products struggle in clinical translation: an in-depth analysis of developmental challenges in the EU.
Journal: Frontiers in medicine
Published: March 26, 2026
Preclinical data and design of a phase I clinical trial of neoantigen-reactive TILs for advanced epithelial or ICB-resistant solid cancers.
Journal: Immuno-oncology technology
Published: February 06, 2025
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 23, 2024
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study.
Journal: Future oncology (London, England)
Published: August 12, 2024
Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 28, 2024
Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors.
Journal: Nature communications
Published: December 04, 2023
Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 30, 2020
Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?
Journal: Current opinion in biotechnology
Published: December 30, 2019
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Journal: Journal of translational medicine
Published: September 12, 2019
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.
Journal: Frontiers in immunology
Published: April 29, 2019
Last Updated: 09/26/2026